Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

D. Pouessel · SciRah

Researcher profile · Semantic Scholar

D. Pouessel

Share profile

D. Pouessel — researcher profile on SciRah

h-index: 31
Works: 150
Citations: 4,163

Most-cited papers

TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors
S. Tagawa, A. Balar, D. Petrylak, A. R. Kalebasty +15 more
2021Journal of Clinical Oncology463 citations Open access
Semantic Scholar
Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial.
P. Wen, A. Stein, M. J. van den Bent, J. De Grève +22 more
2021The Lancet Oncology291 citations Open access
Semantic Scholar
Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
G. Gravis, J. Boher, K. Fizazi, F. Joly +31 more
2015European Urology124 citations Open access
Semantic Scholar
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.
X. Pivot, G. Romieu, M. Debled, J. Pierga +330 more
2019The Lancet117 citations Open access
Semantic Scholar
A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study.
A. Ravaud, C. de la Fouchardiére, P. Caron, A. Doussau +15 more
2017European Journal of Cancer102 citations
Semantic Scholar
Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program
C. Leduc, J. Merlio, B. Besse, H. Blons +16 more
2017Annals of Oncology92 citations Open access
Semantic Scholar
FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?†.
B. V. van Rhijn, L. Mertens, R. Mayr, P. Bostrom +30 more
2020European Urology82 citations
Semantic Scholar
[Management of metastatic bladder cancer].
H. Gauthier, C. Serrate, D. Pouessel, C. le Maignan +2 more
2014La Revue du praticien77 citations
Semantic Scholar
Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15).
G. Gravis, P. Marino, F. Joly, S. Oudard +30 more
2014European Journal of Cancer68 citations
Semantic Scholar
Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomy
F. Claps, M. van de Kamp, R. Mayr, P. Bostrom +28 more
2023BJU International66 citations Open access
Semantic Scholar
PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
B. Rousseau, I. Bièche, É. Pasmant, N. Hamzaoui +52 more
2022Cancer Discovery66 citations Open access
Semantic Scholar
Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study.
A. Cortot, C. Audigier-Valette, O. Molinier, S. Le Moulec +18 more
2020European Journal of Cancer64 citations Open access
Semantic Scholar
Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
P. Lavaud, G. Gravis, S. Foulon, F. Joly +34 more
2017European Urology64 citations
Semantic Scholar
Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.
D. Pouessel, Y. Neuzillet, L. Mertens, M. S. van der Heijden +35 more
2016Annals of Oncology63 citations Open access
Semantic Scholar
Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-naïve metastatic prostate cancer (PCa): Long-term analysis of the GETUG-AFU 15 phase III trial.
G. Gravis, J. Boher, F. Joly, S. Oudard +16 more
201552 citations
Semantic Scholar
Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA).
A. Necchi, D. Pouessel, R. Leibowitz-Amit, A. Flechon +8 more
2018Annals of Oncology49 citations Open access
Semantic Scholar
Risk factors associated with positive surgical margins’ location at radical cystectomy and their impact on bladder cancer survival
F. Claps, M. van de Kamp, R. Mayr, P. Bostrom +17 more
2021World journal of urology45 citations Open access
Semantic Scholar
Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility
A. Moktefi, D. Pouessel, Jing Liu, N. Sirab +8 more
2018Modern Pathology42 citations Open access
Semantic Scholar
Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients.
L. Mertens, F. Claps, R. Mayr, P. Bostrom +31 more
2021Urologic oncology39 citations Open access
Semantic Scholar
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†.
A. Kramar, S. Négrier, R. Sylvester, S. Joniau +80 more
2015Annals of Oncology31 citations Open access
Semantic Scholar
Weekly paclitaxel plus bevacizumab versus docetaxel as second or third-line treatment in advanced non-squamous non-small cell lung cancer (NSCLC): Results from the phase III study IFCT-1103 ULTIMATE.
A. Cortot, C. Audigier-Valette, O. Molinier, S. Le Moulec +14 more
201628 citations
Semantic Scholar
TROPHY-U-01 Cohort 3: Sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PLT)-based regimens.
P. Grivas, D. Pouessel, Chandler Park, P. Barthélémy +13 more
2022Journal of Clinical Oncology27 citations
Semantic Scholar
526O High activity of nivolumab in patients with pathogenic exonucleasic domain POLE (edPOLE) mutated Mismatch Repair proficient (MMRp) advanced tumours
B. Rousseau, I. Bièche, É. Pasmant, V. Simmet +16 more
202025 citations Open access
Semantic Scholar
Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group.
M. Sroussi, R. Elaidi, A. Flechon, M. Lorcet +27 more
2019Clinical Genitourinary Cancer24 citations
Semantic Scholar
LBA24 TROPHY-U-01 cohort 1 final results: A phase II study of sacituzumab govitecan (SG) in metastatic urothelial cancer (mUC) that has progressed after platinum (PLT) and checkpoint inhibitors (CPI)
Y. Loriot, A. Balar, D. Petrylak, S. Tagawa +15 more
202022 citations Open access
Semantic Scholar
Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients with No Progression and with No More than Five Residual Metastatic Lesions Following First-Line Systemic Therapy: A Retrospective Analysis
A. Aboudaram, L. Chaltiel, D. Pouessel, P. Graff-Cailleaud +9 more
2020Cancers22 citations Open access
Semantic Scholar
Hypofractionated Stereotactic Re-irradiation and Anti-PDL1 Durvalumab Combination in Recurrent Glioblastoma: STERIMGLI Phase I Results
D. Pouessel, S. Ken, Valérie Gouazé-Andersson, L. Piram +14 more
2023The Oncologist21 citations Open access
Semantic Scholar
Multilayer spectrum of intratumoral heterogeneity in basal bladder cancer
N. Sirab, D. Drubay, P. Maillé, T. Popova +14 more
2021Journal of Pathology20 citations
Semantic Scholar
Denosumab Toxicity When Combined With Anti‐angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study
A. Guillot, C. Joly, P. Barthélémy, É. Meriaux +16 more
2019Clinical Genitourinary Cancer20 citations
Semantic Scholar
Association between clinically relevant toxicities of pazopanib and sunitinib and the use of weak CYP3A4 and P-gp inhibitors
Camille Azam, Pauline Claraz, C. Chevreau, Camille Vinson +10 more
2020European Journal of Clinical Pharmacology19 citations
Semantic Scholar
715P Nivolumab in pretreated metastatic penile squamous cell carcinoma: Results of the penile cohort from the French AcSé prospective program
D. Pouessel, M. Beylot-Barry, S. Esma, M. de Pontville +16 more
2021Annals of Oncology18 citations Open access
Semantic Scholar
Full analysis from AVENANCE: A real-world study of avelumab first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC).
P. Barthélémy, Y. Loriot, E. Voog, J. Eymard +16 more
2023Journal of Clinical Oncology17 citations
Semantic Scholar
Adjuvant Chemotherapy After Radical Cystectomy for Urothelial Bladder Cancer: Outcome and Prognostic Factors for Survival in a French Multicenter, Contemporary Cohort
D. Pouessel, S. Bastuji-Garin, N. Houédé, D. Vordos +8 more
2017Clinical Genitourinary Cancer17 citations
Semantic Scholar
Nivolumab in metastatic nonclear cell renal cell carcinoma: First results of the AcSe prospective study.
L. Albiges, D. Pouessel, M. Beylot-Barry, G. Bens +11 more
202016 citations
Semantic Scholar
Radiotherapy-PCV versus radiotherapy-temozolomide for IDH-mutant anaplastic astrocytoma: a retrospective multicentre analysis of the French POLA cohort.
V. Esteyrie, C. Dehais, E. Martin, C. Carpentier +7 more
2021The Oncologist15 citations Open access
Semantic Scholar
Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma.
G. Sonpavde, C. Sternberg, Y. Loriot, A. Marabelle +16 more
2022European Journal of Cancer14 citations Open access
Semantic Scholar
Survival Outcomes of Patients with Pathologically Proven Positive Lymph Nodes at Time of Radical Cystectomy with or without Neoadjuvant Chemotherapy
G. Ploussard, B. Pradère, J. Beauval, C. Chevreau +11 more
2020Journal of Clinical Medicine14 citations Open access
Semantic Scholar
Updated outcomes in TROPHY-U-01 cohort 1, a phase 2 study of sacituzumab govitecan (SG) in patients (pts) with metastatic urothelial cancer (mUC) that progressed after platinum (PT)-based chemotherapy and a checkpoint inhibitor (CPI).
S. Tagawa, A. Balar, D. Petrylak, A. Rezazadeh +15 more
2023Journal of Clinical Oncology13 citations
Semantic Scholar
Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?
D. Pouessel, S. Chevret, F. Rolland, G. Gravis +15 more
2016European Journal of Cancer13 citations
Semantic Scholar
Primary analysis of TROPHY-U-01 cohort 3, a phase 2 study of sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) that progressed after platinum (PT)-based therapy.
P. Grivas, D. Pouessel, Chandler Park, P. Barthélémy +16 more
2023Journal of Clinical Oncology11 citations
Semantic Scholar
Skin toxicity of enfortumab vedotin: Proposal of a specific management algorithm
S. Ingen-Housz-Oro, Y. Elshot, S. Segura, Antoine Marchand +11 more
2023Journal of the European Academy of Dermatology and Venereology11 citations Open access
Semantic Scholar
Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cancer
F. Puisset, Mourad Mseddi, L. Mourey, D. Pouessel +3 more
2023Cancers10 citations Open access
Semantic Scholar
Derazantinib (DZB) in combination with atezolizumab (AZB) in patients with solid tumors: Results from the dose-finding phase Ib substudy of FIDES-02.
R. Abdul-Karim, A. Chaudhry, A. Patrikidou, Alejandro Falcón González +10 more
202110 citations
Semantic Scholar
Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH -Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort
C. Dehais, E. Martin, C. Carpentier, E. Uro +9 more
20219 citations
Semantic Scholar
Abiraterone acetate in combination with prednisone in the treatment of prostate cancer: safety and efficacy
C. Manceau, L. Mourey, D. Pouessel, G. Ploussard
2020Expert Review of Anticancer Therapy9 citations
Semantic Scholar
Hypofractionnated stereotactic radiotherapy and anti-PDL1 durvalumab combination in recurrent glioblastoma: Results of the phase I part of the phase I/II STERIMGLI trial.
D. Pouessel, A. Mervoyer, D. Larrieu-Ciron, B. Cabarrou +7 more
20189 citations
Semantic Scholar
Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy in bladder cancer: ready for prime time?
D. Pouessel, H. Gauthier, C. Serrate, C. Pfister +1 more
2014Journal of Clinical Oncology9 citations Open access
Semantic Scholar
Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma.
Lucie Meynard, Derek Dinart, Blandine Delaunay, A. Flechon +17 more
2022European Journal of Cancer8 citations Open access
Semantic Scholar
Vinflunine for the treatment of metastatic transitional cell carcinoma: recent evidence from clinical trials and observational studies
C. Serrate, D. Pouessel, H. Gauthier, C. le Maignan +2 more
20148 citations
Semantic Scholar
Increasing targeted therapy options for patients with relapsed cancer with broader somatic gene panel analysis from the primary tumor: The Profiler02 randomized phase II trial.
O. Trédan, D. Pouessel, N. Penel, S. Chabaud +16 more
2022Journal of Clinical Oncology7 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Flechon×13
Invite
A. Flechon — researcher profile on SciRah
Y. Loriot×11
Invite
Y. Loriot — researcher profile on SciRah
L. Mourey×11
Invite
L. Mourey — researcher profile on SciRah
F. Rolland×10
Invite
F. Rolland — researcher profile on SciRah

×10

Invite

S. Culine — researcher profile on SciRah

Invite

P. Beuzeboc — researcher profile on SciRah

Invite

Y. Allory — researcher profile on SciRah

Invite

G. Gravis — researcher profile on SciRah

Invite

S. Oudard — researcher profile on SciRah

C. Sternberg×6

Invite

C. Sternberg — researcher profile on SciRah

Invite

B. Laguerre — researcher profile on SciRah

Invite

A. Ravaud — researcher profile on SciRah